Prediction of selective estrogen receptor beta agonist using open data and machine learning approach.

Journal: Drug design, development and therapy
PMID:

Abstract

BACKGROUND: Estrogen receptors (ERs) are nuclear transcription factors that are involved in the regulation of many complex physiological processes in humans. ERs have been validated as important drug targets for the treatment of various diseases, including breast cancer, ovarian cancer, osteoporosis, and cardiovascular disease. ERs have two subtypes, ER-α and ER-β. Emerging data suggest that the development of subtype-selective ligands that specifically target ER-β could be a more optimal approach to elicit beneficial estrogen-like activities and reduce side effects.

Authors

  • Ai-Qin Niu
    Department of Gynecology, the First People's Hospital of Shangqiu, Shangqiu, Henan, People's Republic of China.
  • Liang-Jun Xie
    Department of Image Diagnoses, the Third Hospital of Jinan, Jinan, Shandong, People's Republic of China.
  • Hui Wang
    Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Bing Zhu
    Department of Gynecology, the First People's Hospital of Shangqiu, Shangqiu, Henan, People's Republic of China.
  • Sheng-Qi Wang
    Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.